GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
GSK has agreed to a $2.2 billion settlement to resolve the majority of U.S. state court Zantac lawsuits, with an additional $70 million set aside for a qui tam case. The company maintains there is no evidence linking ranitidine to cancer risks.
GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...
GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...
In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...
Taking full advantage of the stock market and investing with confidence ... Value investors should also note GSK's Price/Sales ratio of 2X. A company's earnings performance is important for ...
(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...
adjusted its price target for shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK (LON:GSK)), reducing it to GBP20.00 from a previous GBP21.00. Despite this change, the firm maintained a Buy ...
Thanks largely to news of a crucial legal settlement, GSK ( GSK 5.84%) was one of the better-performing big pharma stocks on Wednesday. Relieved investors showed their appreciation by collectively ...
We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback